After a dramatic multi-year turnaround, shares of 10x Genomics, Inc. (TXG) have surged from a 52-week low near $11 to roughly $64, and investors are now asking whether the stock can realistically reach the psychological milestone of $100. That would represent roughly another 56% gain from recent levels — a meaningful stretch for a life science tools company that remains unprofitable and is already trading above the consensus analyst price target.
The $100 stock price target carries special weight because it is a clean psychological threshold rather than a technical measurement. For a company whose shares traded below $12 within the past year, crossing into triple digits would symbolize a full-scale turnaround and cement its place among high-multiple life science growth names. It is also a level that naturally captures retail and institutional attention, making it a frequent subject of search-driven market discussion.
10x Genomics is a life science technology company that develops instruments, consumables, and software used to study biology at single-cell and spatial resolution. Its flagship platforms include the Chromium single-cell system and the Xenium spatial biology instrument, with the newer Atera platform increasingly central to the growth narrative. The company went public in 2019 and carries a market capitalization of roughly $8.3 billion.
TXG recently traded around $63–$64, near the top of its 52-week range of $11.16 to $64.53. The move reflects a sharp re-rating driven by improving fundamentals rather than broad market drift. The stock's five-year beta of roughly 2.0 underscores its volatility: it can gain or lose ground far faster than the broader market, which cuts both ways when evaluating a target as ambitious as $100.
Several verified fundamentals support continued upside. In its most recent quarter, the company reported revenue of about $151 million, ahead of expectations, with a non-GAAP loss narrower than forecast. Management raised full-year 2026 revenue guidance to a range of $610–$630 million, citing strong early demand for the Atera platform. Gross margin improved to roughly 74%, signaling that core products are high-margin and scaling efficiently even before the business reaches sustained profitability.
Strategic collaborations — including work with major cancer research institutions on single-cell and spatial tumor profiling — also reinforce the long-term thesis that genomics tools are becoming integral to precision medicine and drug discovery. If these partnerships translate into broader consumable pull-through, revenue growth could re-accelerate and support a higher valuation.
The primary obstacle is valuation and profitability. The company still reports negative earnings per share, and its price-to-sales multiple sits well into double digits. More notably, the consensus analyst price target stands near $49.50 — below the current share price — with even the most bullish published target at $65. In other words, Wall Street's base-case expectation is that the stock has already priced in much of the near-term good news.
Reaching $100 would require the market to re-rate the stock to a multiple roughly 50% above even the highest current analyst target. That would likely demand not just revenue growth but a credible, visible path to profitability, sustained gross-margin gains, and continued success with Atera against well-funded competitors in the single-cell and spatial biology space.
Following the recent earnings report, several firms raised their targets: Stifel lifted its target to $50, while Canaccord Genuity moved to $60 and Stephens raised its target to $65. Others, including Morgan Stanley, J.P. Morgan, and Citi, remain more cautious with neutral ratings and targets in the $40–$50 range. The dispersion — from roughly $40 to $65 — reflects genuine disagreement about whether the recent momentum can persist. Notably, none of these targets approach $100, meaning the selected objective sits far outside the current analyst consensus and would require a fundamentally different earnings trajectory.
From a technical analysis standpoint, the prior 52-week high near $64.50 is the immediate resistance level that must first be cleared and held. A sustained breakout above that zone would remove the last remaining overhang from the stock's recent peak. On the downside, the upper $40s to low $50s — where the stock consolidated before its latest leg higher — represent a meaningful support zone that could act as a floor if momentum fades. The $100 level itself would be the next major psychological resistance, but it is not anchored by prior price history, making it more of an aspirational target than a defined supply zone.
For traders monitoring whether TXG can sustain its momentum toward higher price targets, Tickeron's AI Daily Buy/Sell Signals offer an automated way to track changing conditions. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on evolving market behavior, technical patterns, and AI-driven analysis. Traders can use these signals to surface new opportunities, monitor existing positions, and identify shifting market trends more efficiently than manual screening alone allows.
On balance, a move to $100 appears plausible only over a longer time horizon and would require conditions that are not yet in place. The strongest supports are real: accelerating Atera adoption, a high gross margin, and upwardly revised revenue guidance give the growth story tangible momentum. The largest headwinds are equally real: the company remains unprofitable, and its shares already trade above the average analyst price target, with even the most bullish published target at $65. Investors should monitor Atera-related revenue growth, gross-margin trends, the path toward profitability, and whether the stock can decisively hold above its 52-week high. Until the market re-rates the business well beyond current analyst expectations, $100 remains an ambitious — not imminent — objective.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TXG has been loosely correlated with COIN. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if TXG jumps, then COIN could also see price increases.
| Ticker / NAME | Correlation To TXG | 1D Price Change % | ||
|---|---|---|---|---|
| TXG | 100% | +1.96% | ||
| COIN - TXG | 56% Loosely correlated | +8.20% | ||
| CLSK - TXG | 54% Loosely correlated | -4.92% | ||
| RIOT - TXG | 54% Loosely correlated | -5.48% | ||
| COMP - TXG | 52% Loosely correlated | -1.43% | ||
| TEM - TXG | 49% Loosely correlated | +9.06% | ||
More | ||||
| Ticker / NAME | Correlation To TXG | 1D Price Change % |
|---|---|---|
| TXG | 100% | +1.96% |
| Services to the Health Industry industry (43 stocks) | 25% Poorly correlated | +0.67% |
| Health Services industry (242 stocks) | 7% Poorly correlated | +0.79% |